AstraZeneca has entered a deal to acquire Omniose, following a three-year exclusive research collaboration between the two organizations that both sides described as productive.

Christian Harding, CSO and co-founder of Omniose, frames the acquisition as the culmination of years of partnership. “This milestone reflects the work of exceptional and complementary teams,” Harding says. “AstraZeneca has been a trusted partner for several years, and this acquisition gives our platform the best chance to reach the patients it was built to serve.”¹

Under the terms of the agreement, Omniose is set to become a wholly owned subsidiary of AstraZeneca and will join the company’s Infectious Disease Unit.¹ The deal brings Omniose’s proprietary bioconjugation platform and expertise into AstraZeneca, complementing the larger company’s existing capabilities and supporting its preclinical vaccine programs.¹ Financial details of the deal have yet to be disclosed.

What problem does bioconjugation solve?

Conventional conjugate vaccine manufacturing requires chemical cross-linking of bacterial polysaccharide antigens to immunogenic carrier proteins, a process that is complex and makes the resulting vaccines difficult to produce reproducibly and to characterize, requiring extensive release testing before use.² The non-specific nature of that cross-linking, and the conditions chemical conjugation requires, can also lead to undesired modifications of epitopes that may affect the quality of the immune response generated against the polysaccharide antigen.² Bioconjugation offers what is described as an elegantly simple alternative to chemical conjugation, producing and linking the antigen and carrier protein within a single cell.²

Why does this technology matter for public health?

Polysaccharide conjugate, or glycoconjugate, vaccines have already proven enormously successful at reducing disease and death from infections caused by bacterial pathogens including Haemophilus influenzae type B, Streptococcus pneumoniae, Neisseria meningitidis, and Salmonella typhi.² These vaccines carry an added public health benefit by preventing the infections they target, while also helping to fight antimicrobial resistance by reducing the overall use of antibiotics.²

The underlying bioconjugation science has already moved through clinical development in other hands. Omniose co-founder Mario Feldman provided the work leading to the industrialization of bioconjugate vaccine technologies by GSK, following that company’s acquisition of GlycoVaxyn/Limmatech’s bioconjugate platform technology, for vaccine candidates against Shigella, which is now in Phase IIB development, and Klebsiella pneumoniae, now in Phase I development.²

Janssen, now known as Johnson & Johnson Innovative Medicine, separately licensed the same underlying platform to develop a bioconjugate vaccine against extraintestinal pathogenic Escherichia coli targeting nine serotypes, advancing that candidate into Phase III development.²

Benjamin Moutier, senior vice president, infectious disease, AstraZeneca, points to the scientific differentiation Omniose’s platform offers. “Omniose’s bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections,” Moutier says. “Building on the strong scientific collaboration between our teams, we look forward to advancing these programs and realizing the potential of this technology for patients.”

What comes next for the combined vaccine programs?

With the acquisition complete, Omniose’s bioconjugation platform now sits inside AstraZeneca’s Infectious Disease Unit, where it is positioned to support the unit’s existing preclinical vaccine programs targeting serious bacterial infections.¹

Timothy Cooke, CEO of Omniose, describes the acquisition as a shared win built around a common mission. “The acquisition by AstraZeneca is a great outcome for both organizations,” Cooke says. “We share a vision for bringing the best science and talent together to address serious bacterial infections, which are increasingly complicated by antimicrobial resistance.”

Sources

1. Omniose Announces Its Acquisition by AstraZeneca Omniose November 10, 2026 https://www.businesswire.com/news/home/20261110984674/en/Omniose-Announces-Its-Acquisition-by-AstraZeneca
2. Omniose Technology Section Omniose Date Accessed November 10, 2026 https://omniose.com/technology/